**Short Communication**

**Effects of a short-term overfeeding with fructose or glucose in healthy young males**

Emilienne Tudor Ngo Sock†, Kim-Anne Lê†, Michael Ith2, Roland Kreis2, Chris Boesch2 and Luc Tappy1*

1Faculty of Biology and Medicine, Department of Physiology, University of Lausanne, Rue du Bugnon 7, CH-1005 Lausanne, Switzerland
2Department of Clinical Research, University of Bern, Bern, Switzerland

(Received 18 May 2009 – Revised 9 September 2009 – Accepted 12 October 2009 – First published online 24 November 2009)

Consumption of simple carbohydrates has markedly increased over the past decades, and may be involved in the increased prevalence in metabolic diseases. Whether an increased intake of fructose is specifically related to a dysregulation of glucose and lipid metabolism remains controversial. We therefore compared the effects of hypercaloric diets enriched with fructose (HFrD) or glucose (HGlcD) in healthy men. Eleven subjects were studied in a randomised order after 7 d of the following diets: (1) weight maintenance, control diet; (2) HFrD (3·5 g fructose/kg fat-free mass (ffm) per d, +35 % energy intake); (3) HGlcD (3·5 g glucose/kg ffm per d, +35 % energy intake). Fasting hepatic glucose output (HGO) was measured with 6,6-2H2-glucose. Intrahepatocellular lipids (IHCL) and intramyocellular lipids (IMCL) were measured by 1H magnetic resonance spectroscopy. Both fructose and glucose increased fasting VLDL-TAG (HFrD: +59 %, P<0·05; HGlcD: +31 %, P=0·11) and IHCL (HFrD: +52 %, P<0·05; HGlcD: +58 %, P=0·06). HGO increased after both diets (HFrD: +5 %, P<0·05; HGlcD: +5 %, P=0·05). No change was observed in fasting glycaemia, insulin and alanine aminotransferase concentrations. IMCL increased significantly only after the HGlcD (HFrD: +24 %, NS; HGlcD: +59 %, P<0·05). IHCL and VLDL-TAG were not different between hypercaloric HFrD and HGlcD, but were increased compared to values observed with a weight maintenance diet. However, glucose led to a higher increase in IMCL than fructose.

**Intrahepatic lipids: Intramyocellular lipids: VLDL-TAG: Hepatic insulin sensitivity**

Consumption of refined sugars has markedly increased over the past decades(1). In the Western world, these are mostly consumed under two forms: either as sucrose, mainly extracted from beet, and constituted of one molecule of fructose linked to one molecule of glucose; or as high-fructose corn syrup, which consists in a mixture of free fructose and glucose, the most common form being characterised by a fructose:glucose ratio of 55:45(2). Recently, the drastic increase in high-fructose corn syrup consumption at the detriment of sucrose has raised much concern(3). Several authors have suggested that such increase in free fructose consumption may be linked to the development of obesity and the metabolic syndrome. Indeed, both in rodents and human subjects, high-fructose diets (HFrD) lead to hypertriaclylglycerolaemia, insulin resistance and accumulation of ectopic lipid in the liver and the muscle, known as intrahepatocellular lipids (IHCL) and intramyocellular lipids (IMCL), respectively(4–6). These deleterious effects were attributed to the fact that fructose, by bypassing the major regulatory point of glycolysis, rapidly leads to an excess of triose phosphates in hepatocytes, which may be used as substrates for de novo lipogenesis. Several rodents(7,8) and human studies(9) have previously shown that fructose was a more potent stimulator of lipogenesis than glucose. However, most of these studies were performed in an acute setting, and it remains therefore unknown whether chronic fructose-induced alterations of lipid homoeostasis are due to specific fructose properties, or are merely the result of energy and/or sugar overloading. The aim of the present study was to compare the effects of a hypercaloric 7-d HFrD v. high-glucose diet (HGlcD) on ectopic lipids, glucose homoeostasis and plasma lipid profile.

**Subjects and methods**

**Subjects**

Eleven healthy non-smoking male volunteers (24·6 (SEM 0·6) years; means with their standard errors) participated in the study. These two authors contributed equally to the work.

Abbreviations: HFrD, high-fructose diets; HGlcD, high-glucose diets; IHCL, intrahepatocellular lipids; IMCL, intramyocellular lipids.

* Corresponding author: Luc Tappy, fax +41 21 6925595, email luc.tappy@unil.ch
study. According to a physical examination and a brief medical history, all subjects were in good health with a BMI between 19 and 25 kg/m\(^2\) and were moderately physically active (<1 h/week). They were not taking any medications and did not regularly consume alcohol or sugar-sweetened beverages.

**Study design and diet**

Each subject consumed, in a crossover randomised order, the following diets: (1) a 7-d weight maintenance diet (total energy intake equal to predicted basal energy requirement\(^{10}\times 1-6\)), containing 55 % carbohydrate (of which 11 % simple sugars), 30 % fat and 15 % protein; (2) the same weight maintenance diet supplemented with 3·5 g fructose/kg fat-free mass per d: HFrD; or (3) the weight maintenance diet supplemented with 3·5 g glucose/kg fat-free mass per d: HGlcD. Both HFrD and HGlcD corresponded to an energy overload corresponding to +35 % energy requirements. The study was performed on an outpatient basis, and during the 3 d preceding the metabolic investigations, subjects were provided with all the dietary constituents as pre-packed food items with instruction as to how and when to consume them. Fructose and glucose were administered as a 20 % solution with the three main meals. A 2–3-week washout period separated the three dietary conditions. Leisure sport activity was restricted to <1 h/week throughout the study period. Compliance was assessed by interview.

The present study was conducted according to the guidelines laid down in the Declaration of Helsinki, and all procedures involving human subjects/patients were approved by the ethical board of Lausanne University School of Biology and Medicine. Written informed consent was obtained from all subjects.

**Metabolic investigation**

Subjects reported at 07.00 hours to the metabolic unit of the Lausanne University Hospital after a 10-h fast. Upon arrival, subjects were asked to void, and body composition was estimated from subcutaneous skinfold thickness measurements at the biceps, triceps, subscapular and suprailiac sites\(^{11}\). Participants thereafter rested quietly in a bed in a semi-recumbent position, and an indwelling catheter was inserted into the vein of the right wrist for blood sampling. A second indwelling catheter was inserted into an antecubital vein of the other arm for infusion of 6,6-\(^2\)H\(_2\) glucose. Fasting hepatic glucose output was assessed in basal condition after a 2-h 6,6-\(^2\)H\(_2\) glucose infusion (bolus: 2 mg/kg; continuous: 20 \(\mu\)g/kg per min) by glucose isotope dilution analysis using Steele’s equations for steady-state conditions\(^{12}\). Blood was collected during baseline for measurement of plasma concentrations of glucose, lactate, insulin, non-esterified fatty acids, baseline for measurement of plasma concentrations of glucose, lactate, insulin, non-esterified fatty acids, baseline for measurement of plasma concentrations of glucose, lactate, insulin, non-esterified fatty acids, and substrates utilisation were continuously assessed in basal condition after a 2-h 6,6-\(^2\)H\(_2\) glucose infusion using Steele’s equations for steady-state conditions\(^{12}\). Baseline for measurement of plasma concentrations of glucose, lactate, insulin, non-esterified fatty acids, baseline for measurement of plasma concentrations of glucose, lactate, insulin, non-esterified fatty acids, and substrates utilisation were continuously assessed in basal condition after a 2-h 6,6-\(^2\)H\(_2\) glucose infusion using Steele’s equations for steady-state conditions\(^{12}\). Baseline for measurement of plasma concentrations of glucose, lactate, insulin, non-esterified fatty acids, baseline for measurement of plasma concentrations of glucose, lactate, insulin, non-esterified fatty acids, and substrates utilisation were continuously assessed in basal condition after a 2-h 6,6-\(^2\)H\(_2\) glucose infusion using Steele’s equations for steady-state conditions\(^{12}\). 

Fasting hepatic insulin sensitivity index was calculated as\(^{14}\):

\[
\text{Fasting hepatic insulin sensitivity index} = \left(\frac{100}{\text{hepatic glucose output} \times \text{insulin}}\right).
\]

**Analytical procedures**

Plasma was immediately separated from blood by centrifugation at 4°C for 10 min at 3600 rpm and stored at −20°C. Colorimetric methods were used to assess plasma concentrations of NEFA (kit from Wako Chemicals, Freiburg, Germany) and TAG (kit from Biomérieux Vetec, Inc., Durham, Switzerland). Commercial RIA kits were used for the determination of plasma insulin and leptin (LINCO Research, St Charles, MO, USA). Subfractions of lipoproteins were separated by ultracentrifugation. \(\beta\)-Hydroxybutyric acid and lactate concentrations were determined enzymatically using kits from Boehringer (Mannheim, Germany). Plasma glucose concentration was measured by the glucose oxidase method using a Beckman glucose analyzer II (Beckman Instruments, Fullerton, CA, USA). Plasma 6,6-\(^2\)H\(_2\) glucose isotopic enrichment was measured by GC–MS (Hewlett Packard Instruments, Palo Alto, CA, USA), as previously described\(^{15}\).

**\(^1\)H Magnetic resonance spectroscopy**

All \(^1\)H-magnetic resonance spectroscopy examinations were performed on a clinical 1·5 T MR scanner with data acquisition (single-voxel localisation with 20 ms echo time) and processing similar to a protocol described earlier for IMCL\(^{16}\) and IHCL\(^{17}\). Fat content was expressed in mmol/kg.

**Statistical analysis**

Data are expressed as means with their standard errors. Statistical analyses were performed with STATA version 8.2 and \(P<0.05\) was considered statistically significant. Because IHCL values were not normally distributed, they were converted into log values before statistical analysis. All the data were analysed by using repeated-measures ANOVA. *Post hoc* comparisons were done by using the Student’s paired \(t\) test.

**Results**

All subjects significantly gained weight after both hypercaloric diets (Table 1). HFrD increased VLDL by 59 (SEM 24) % (range \(−28\) to \(+197\)), \(P<0.05\) and IHCL by 52 (SEM 13) % (range \(−27\) to \(+203\)), \(P<0.05\). With HGlcD, increases in similar magnitudes were observed, but did not reach statistical significance due to large interindividual variations in the response to hypercaloric diets (VLDL-TAG: +31 (SEM 20) % (range \(−44\) to \(+139\)), \(P=0.11\); IHCL: +58 (SEM 23) % (range \(−29\) to \(+226\)), \(P=0.06\) (Fig. 1). IHCL and VLDL-TAG were not different with HFrD and HGlcD. No change was observed in fasting glycemia, insulin and alanine aminotransferase concentrations (Table 1). Both diets significantly decreased NEFA and ketone bodies (Table 1). IMCL significantly increased only after the HGlcD (fructose: +49 (SEM 23) % (range \(−23\) to \(+239\)), NS; glucose: +84 (SEM 86) % (range \(−20\) to \(+319\)), \(P<0.05\)). Carbohydrate oxidation increased with a concomitant decrease in lipid oxidation after both hypercaloric diets. Hepatic glucose output increased after both diets (HFrD: \(+5\%\), \(P<0.05\); HGlcD: \(+5\%\), \(P<0.05\); Table 1). Hepatic insulin sensitivity index decreased to the same extent after HFrD and HGlcD, but failed to reach significance.
Table 1. Anthropometric and metabolic parameters after the weight maintenance, the high-fructose (HFrD) and high-glucose diets (HGlcD) (Mean values with their standard errors)

<table>
<thead>
<tr>
<th></th>
<th>Wt maintenance</th>
<th>HFrD</th>
<th>HGlcD</th>
<th>P*</th>
<th>P†</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Anthropometric parameters</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Body wt (kg)</td>
<td>71.9 ± 1.6</td>
<td>72.5 ± 1.7</td>
<td>&lt;0.01</td>
<td>72.9 ± 1.5</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>Body fat (%)</td>
<td>15 ± 1</td>
<td>16 ± 1</td>
<td>&lt;0.05</td>
<td>16 ± 1</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td><strong>Metabolic parameters</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glucose (mg/l)</td>
<td>900 ± 20</td>
<td>920 ± 20</td>
<td>NS</td>
<td>900 ± 20</td>
<td>NS</td>
</tr>
<tr>
<td>Lactate (mmol/l)</td>
<td>0.98 ± 0.06</td>
<td>1.23 ± 0.08</td>
<td>&lt;0.01</td>
<td>1.3 ± 0.1</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Insulin (μmol/l)</td>
<td>54.0 ± 3.6</td>
<td>60.0 ± 1.8</td>
<td>NS</td>
<td>58.2 ± 3.6</td>
<td>NS</td>
</tr>
<tr>
<td>Non-esterified fatty acids (μmol/l)</td>
<td>560 ± 40</td>
<td>354 ± 23</td>
<td>&lt;0.01</td>
<td>330 ± 36</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>β-Hydroxybutyrate (mmol/l)</td>
<td>0.07 ± 0.01</td>
<td>0.02 ± 0.01</td>
<td>&lt;0.01</td>
<td>0.01 ± 0.01</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Uric acid (μmol/l)</td>
<td>313 ± 9</td>
<td>344 ± 13</td>
<td>&lt;0.05</td>
<td>330 ± 9</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>ALAT (U/l)</td>
<td>21 ± 2</td>
<td>25 ± 3</td>
<td>NS</td>
<td>26 ± 4</td>
<td>NS</td>
</tr>
<tr>
<td>ASAT (U/l)</td>
<td>24 ± 1</td>
<td>25 ± 1</td>
<td>NS</td>
<td>25 ± 2</td>
<td>NS</td>
</tr>
<tr>
<td><strong>Indirect calorimetry</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Energy expenditure (kJ/min)</td>
<td>4.14 ± 0.04</td>
<td>4.18 ± 0.04</td>
<td>NS</td>
<td>4.23 ± 0.04</td>
<td>NS</td>
</tr>
<tr>
<td>Carbohydrates oxidation (mg/kg per min)</td>
<td>8.3 ± 0.8</td>
<td>11.5 ± 0.1</td>
<td>&lt;0.01</td>
<td>12.5 ± 0.4</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Lipid oxidation (mg/kg per min)</td>
<td>0.6 ± 0.1</td>
<td>0.4 ± 0.1</td>
<td>&lt;0.01</td>
<td>0.3 ± 0.1</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td><strong>Hepatic metabolism</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatic insulin sensitivity index</td>
<td>5.5 ± 0.3</td>
<td>4.5 ± 0.1</td>
<td>0.06</td>
<td>4.7 ± 0.3</td>
<td>NS</td>
</tr>
<tr>
<td>Fasting HGO (mg/kg per min)</td>
<td>2.2 ± 0.1</td>
<td>2.3 ± 0.1</td>
<td>&lt;0.05</td>
<td>2.3 ± 0.1</td>
<td>0.05</td>
</tr>
<tr>
<td><strong>Lipidic profile</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total TAG (mmol/l)</td>
<td>0.9 ± 0.1</td>
<td>1.2 ± 0.2</td>
<td>&lt;0.05</td>
<td>1.2 ± 0.2</td>
<td>NS</td>
</tr>
<tr>
<td>HDL-cholesterol (mmol/l)</td>
<td>1.1 ± 0.1</td>
<td>1.1 ± 0.1</td>
<td>NS</td>
<td>1.1 ± 0.1</td>
<td>NS</td>
</tr>
<tr>
<td>LDL-cholesterol (mmol/l)</td>
<td>2.4 ± 0.1</td>
<td>2.2 ± 0.1</td>
<td>NS</td>
<td>2.2 ± 0.1</td>
<td>NS</td>
</tr>
<tr>
<td>Total cholesterol (mmol/l)</td>
<td>4 ± 0.2</td>
<td>3 ± 0.2</td>
<td>NS</td>
<td>3.8 ± 0.2</td>
<td>NS</td>
</tr>
</tbody>
</table>

ALAT, Ala aminotransferase; ASAT, aspartate aminotransferase; HGO, hepatic glucose output.

*HFrD v. weight maintenance.
†HGlcD v. weight maintenance.

Discussion

It has been known for decades that a HFrD leads, in human subjects or in rodents, to several features of the metabolic syndrome, including hypertriglyceridaemia\(^{16,18,19}\), insulin resistance\(^{20–22}\) and ectopic lipid deposition\(^{21}\). However, in several of these studies, high fructose intake was also associated with a high energy intake, but was not compared to a high glucose intake. This made it impossible to sort out the effects of fructose per se and those of overfeeding with simple sugars. In the present study, we show that a hyper-caloric HGlcD leads to many of the metabolic alterations associated with a HFrD.

Few studies have directly compared the effects of fructose v. glucose. When administered as part of a test meal, fructose stimulates hepatic de novo lipogenesis to a greater extent than glucose\(^{9}\), and causes higher postprandial and 24-h triglyceridaemia\(^{23,24}\). These differences observed after acute administration are best explained by the distinct metabolism of these two carbohydrates. Unlike glucose, fructose metabolism does not require the action of insulin. After ingestion, fructose is directly delivered in the liver, which constitutes the main site of its metabolism. In hepatocytes, fructose is degraded into triose phosphates, which can be diverted into one of the following pathways: oxidation, lactate and glucose production or de novo lipogenesis\(^{25}\).

The chronic effects of a HFrD v. a HGlcD have been less described. In a previous study, Bantle et al.\(^{26}\) found that fructose, but not glucose, increased fasting and postprandial TAG in healthy men. However, both sugars were consumed as part of an isocaloric, weight maintenance diet. In obese human subjects, overfeeding with fructose, but not with glucose, has been reported to produce a slight increase in intra-visceral fat over a 10-week period and to enhance postprandial plasma TAG\(^{27}\). In rodents, hypercaloric HFrD, but not HGlcD, led to higher IHCL deposition and plasma TAG after 2 weeks\(^{28}\). Analysis of liver tissue revealed that both fructose and glucose consumption stimulated lipogenic genes expression; however, only fructose decreased hepatic expression and activity of genes involved in lipid oxidation. It was therefore suggested that fructose-induced inhibition of hepatic lipid oxidation may be responsible for the IHCL accumulation\(^{28}\).

The present results are at odds with some of these reports. Fructose overfeeding indeed increased IHCL and VLDL-TAG, as reported in rodents\(^{28}\) and in human subjects\(^{29}\). The presently reported increase in IHCL was, however, of a smaller magnitude than in our previous study\(^{29}\), and showed considerable inter-individual variability. Part of this variability may be explained by genetic factors, since we have reported that offsprings of patients with type 2 diabetes have fructose-induced increases in IHCL\(^{29}\). Inter-individual differences in insulin sensitivity may also play a role since hepatic insulin resistance has been shown to be strongly associated with intrahepatic fat\(^{30}\). However, and in contrast with what was reported in rodents\(^{28}\), we observed that glucose overfeeding during 7 d also increased IHCL and plasma VLDL-TAG. When expressed as the percentage change from values observed with the control, weight maintenance diet, fructose and glucose led to similar increases in IHCL and...
Fructose overfeeding also increases IMCL in healthy subjects and in offsprings of patients with type 2 diabetes, and here again, a considerable inter-individual variation is likely to be responsible for failure to reach statistical significance in the present study. The apparent larger increase in IMCL after glucose may nonetheless reflect the different pathways used for the metabolism of these two sugars. Contrarily to fructose, a major portion of a glucose load is directly metabolised in muscle, where it stimulates glucose oxidation\(^{(31)}\). A concomitant inhibition of muscle lipid oxidation may therefore favour deposition of intramyocellular lipid.

Glucose and fructose overfeeding led to similar decreases in plasma NEFA, indicating suppression of adipose tissue lipolysis. This observation may appear surprising since insulin is the major factor inhibiting lipolysis and glucose is expected to produce much larger increase in insulin concentrations. Adipocytes are, however, extremely sensitive to insulin, and the slight increase in plasma insulin elicited by oral fructose has been reported to be sufficient to significantly inhibit lipolysis\(^{(32)}\). Fructose overfeeding also suppressed basal, post-absorptive NEFA, as previously reported\(^{(33)}\). The mechanisms remain hypothetical at this point, but may involve changes in the expression of genes involved in lipid storage and/or lipid oxidation.

In summary, our present data indicate that a short-term overfeeding with either fructose or glucose leads within 7 d to several potentially deleterious metabolic alterations in healthy human subjects. Both sugars increased plasma TAG, which may increase cardiovascular risk\(^{(34)}\). Both sugars also led to intrahepatic fat deposition, and such effect may, in the long term, favour the development of non-alcoholic fatty liver disease. They also led to slight alterations of hepatic insulin sensitivity index. Finally, glucose overfeeding led to a significant deposition of ectopic fat in muscle, which may, in the long term, favour muscle insulin resistance\(^{(35)}\). Both diets were hypercaloric, and it is possible that excess energy intake rather than specific effects of sugars was responsible for these metabolic alterations. In support of this hypothesis, we have recently reported that a short-term overfeeding with 30 \% excess energy as saturated fat also increased IHCL concentrations\(^{(17)}\). Fat overfeeding, however, failed to increase plasma TAG concentrations, suggesting that sugars may have additional effects on plasma lipid concentrations. From a practical point of view, these results suggest that high energy and high sugar intakes may confer a risk for the development of metabolic disorders. In this perspective, reducing sugar intake may be a primary target for prevention of metabolic diseases.

**Acknowledgements**

The present work was supported by grant no. 121995 from the Swiss National foundation for Science. E. T. N. S., K.-A. L., and L. T. performed the metabolic tests; K.-A. L. and L. T. designed the experiment; M. I., R. K. and C. B. performed the NMR measurements; E. T. N. S. and K.-A. L. performed the statistical analysis; K.-A. L. drafted the manuscript; all authors revised the manuscript. The study was performed at the Department of Physiology, University of Lausanne, Lausanne, Switzerland. We thank the staff of the Department of Physiology of Lausanne for their excellent work.
assistance, and all the volunteers for their participation and commitment. The authors state that there are no conflicts of interest.

References